Why the study?
Does sequential and combined use of IPV and OPV provide high immunogenicity and safety against poliovirus in infants?
Does sequential and combined use of IPV and OPV provide high immunogenicity and safety against poliovirus in infants?
Sequential use of IPV followed by OPV is feasible, safe, and highly immunogenic in infants, providing a strategy to reduce vaccine-associated paralysis.
High seropositivity supports sequential IPV-OPV schedules in infants; leaves open randomized trials for paralysis prevention.
To determine the feasibility of a vaccination strategy that would reduce the risk of vaccine-associated paralysis while retaining a barrier against the spread of wild poliovirus, a 2-year project was undertaken using enhanced-potency inactivated poliovirus vaccine (IPV) administered at 2 and 3 months of age followed by doses of both IPV and oral poliovirus vaccine (OPV) administered at 4 and 9 months of age. Vaccination coverage by 12 months of age with three or more doses of IPV and two doses of OPV among 16,566 infants eligible for vaccination was > 95% and > 80%, respectively. Among 51 children from whom blood samples were obtained 45 days after their third dose of IPV and first dose of OPV, 100% had serum neutralizing antibodies (reciprocal titer > or = 10) to all three poliovirus types. No cases of paralytic poliomyelitis due to either wild or vaccine-related strains were reported. The project demonstrated the feasibility, safety, and high immunogenicity of sequential use of IPV followed by OPV in Romania.
No takes yet. Share an insight, caveat, or question.
Ion-Nedelcu et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: